JPMorgan Chase & Co. Begins Coverage on Aeglea Bio Therapeutics (AGLE)

Equities researchers at JPMorgan Chase & Co. initiated coverage on shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) in a report issued on Thursday, The Fly reports. The firm set an “overweight” rating on the biotechnology company’s stock.

A number of other equities research analysts have also weighed in on the stock. ValuEngine lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Aeglea Bio Therapeutics presently has an average rating of “Buy” and an average target price of $21.75.

Shares of AGLE opened at $8.09 on Thursday. The firm has a market cap of $237.76 million, a PE ratio of -3.80 and a beta of 1.07. Aeglea Bio Therapeutics has a 1-year low of $6.31 and a 1-year high of $12.00.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.27). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 71.39%. As a group, analysts predict that Aeglea Bio Therapeutics will post -1.7 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of Aeglea Bio Therapeutics by 5.4% in the 4th quarter. Geode Capital Management LLC now owns 162,597 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 8,310 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Aeglea Bio Therapeutics by 72.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 286,225 shares of the biotechnology company’s stock valued at $2,144,000 after buying an additional 119,904 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Aeglea Bio Therapeutics in the 4th quarter valued at $156,000. Bank of America Corp DE grew its position in shares of Aeglea Bio Therapeutics by 299.9% in the 4th quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 12,858 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Aeglea Bio Therapeutics by 11.6% in the 4th quarter. Bank of New York Mellon Corp now owns 49,470 shares of the biotechnology company’s stock valued at $371,000 after buying an additional 5,150 shares during the last quarter. Institutional investors own 56.89% of the company’s stock.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Featured Article: Blue-Chip Stocks

The Fly

Analyst Recommendations for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.